App aims to leverage digital technology to significantly reduce pharmacy costs.
Veracity Benefits and Levrx Technology have announced a strategic partnership with the launch of the Veracity Rx app. The app was developed with the goal of leveraging advanced digital technology to significantly reduce pharmacy costs by 40%-60% below the national average. According to a joint press release, the app provides members with efficient access to their pharmacy benefits and offers personalized, real-time data and insights for saving on medications.1
“Our collaboration with Levrx Technology is instrumental in streamlining our mission to digitize and promote pharmacy programs that yield optimal health outcomes and deliver financial results,” said James Davie, chief revenue officer, Veracity Benefits, in the press release. “The VeracityRx App is a testament to our commitment to providing cutting-edge solutions that benefit both employers and employees."
According to the companies, the primary features of the platform include increased benefit programs, improved employee satisfaction, reduced disruptions, simplified prescription management, and the opportunity for brokers to provide a unique solution to clients.1
"Working with organizations like Veracity Benefits, which prioritize transparency and advocacy for their members, is revolutionizing the pharmacy experience,” said Vikram Agrawal, CEO, president, Levrx Technology, in the release. “The VeracityRx App is a result of our joint commitment to enhancing efficiency and cost-effectiveness in the healthcare industry."
This isn’t the first time Levrx has teamed up with another company in an effort to address the high cost of prescription medications. Last year, the company announced a collaboration with Drexi aimed at helping patients find the best deals on prescription drugs. According to the company, its platform provides Drexi members with the ability to request a switch to lower cost medications or pharmacy locations, allowing Drexi to focus on helping members save money and navigate the more complicated aspects of the pharma industry.2
"Our goal was to put the member back in the driver's seat by providing them with a tool that tells them exactly where they can get their medications for the very best price in their market," said Anthony Masotto, executive vice president of Pharmacy, Drexi, in the release. "Our partnership with Levrx provides real-time and reliable information to members so they can easily choose what's best for them."
"Our technology gives patients and providers the information needed at the point-of-care to find the best Rx option. Together, Drexi and Levrx help patients save money and improve the pharmacy experience," added Vikash Agrawal, executive chairman, Levrx Technology.
References
1. Introducing The VeracityRx App: Bringing the Power of AI to Prescription Drug Savings. PR Newswire. January 31, 2024. Accessed January 31, 2024. https://www.prnewswire.com/news-releases/introducing-the-veracityrx-app-bringing-the-power-of-ai-to-prescription-drug-savings-302049435.html
2. DREXI PARTNERS WITH LEVRX TECHNOLOGY TO EMPOWER MEMBERS TO FIND THE BEST PRESCRIPTION PRICES. PR Newswire. May 10, 2023. Accessed January 31, 2024. https://www.prnewswire.com/news-releases/drexi-partners-with-levrx-technology-to-empower-members-to-find-the-best-prescription-prices-301821367.html
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.